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Background-—The metabolic signature associated with subclinical diastolic left ventricular (LV) dysfunction in the population
remains ill defined.
Methods and Results-—In 711 randomly recruited Flemish (50.8% women; mean age, 50.8 years), we assessed echocardiographic
Doppler indexes of diastolic LV function in relation to 44 circulating metabolites determined by nuclear magnetic resonance
spectroscopy. In multivariable-adjusted regression analysis with Bonferroni correction of significance levels applied, peak a’
decreased (P≤0.048) and e’/a’ increased (P≤0.044) with circulating tyrosine, high-density lipoprotein apolipoproteins,
glucose+glutamine, and an unidentified molecule. Effect sizes expressed per 1-SD increment in the metabolite ranged from
0.277 to 0.203 cm/s for peak a’ and from +0.047 to +0.054 for e’/a’. In addition, peak a’ decreased (P≤0.031) with
glucose+2-aminobutyrate (0.261 cm/s) and glucose+2-phosphoglycerate (0.209 cm/s). In partial least square discriminant
analysis (PLS-DA), metabolites associated with normal diastolic LV function (n=538) included glucose+glutamine, glucose+2-
aminobutyrate, and glucose+2-phosphoglycerate, whereas those siding with abnormal function encompassed 4-aminobutyrate,
4-hydroxybutyrate, creatinine, and phosphocholine. In receiver operating characteristics plots, adding 3 latent factors identified by
PLS-DA to prohormone brain natriuretic peptide increased (P<0.0001) the area under the curve from 0.64 (95% CI, 0.58–0.68) to
0.73 (0.68–0.78).
Conclusions-—In a general population, circulating metabolites indicative of energy substrate utilization and protection against
oxidative stress differentiated normal from abnormal diastolic LV function. These findings improve our understanding of the
pathophysiology underlying deterioration of diastolic LV function and potentially point to new targets for prevention and treatment
of this condition. ( J Am Heart Assoc. 2016;5:e002681 doi: 10.1161/JAHA.115.002681)
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P revalence of heart failure (HF) among adults living inEurope amounts to 15 million1 and 5 million in the
United States,2 of whom approximately half have diastolic HF
with a 5-year mortality rate in excess of 50%.1,3 In population
studies,4–6 frequency of asymptomatic diastolic left ventric-
ular (LV) dysfunction, as diagnosed by echocardiography, is as
high as 27%. Availability of biomarkers helping to understand
the underlying pathophysiology and identify the large pool of
individuals with subclinical diastolic LV dysfunction at high
risk of HF is key to prevention and timely treatment.1
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Metabolomics is the systematic study of small-molecule
metabolite profiles in biological fluids.7,8 Studies of HF patients
matched with healthy controls showed a different metabolic
signature in serum9 and urine.9,10 Recently, Cheng et al.
demonstrated that over and beyond classical risk factors and B-
type natriuretic peptide (BNP), circulating plasma metabolites
had diagnostic value in assessing HF-related metabolic distur-
bances and predicting hospitalizations and mortality.8 How-
ever, the utility of metabolite profiling in HF remains
uncertain.11 Findings in symptomatic patients cannot be
extrapolated to subclinical disease, in which biomarkers would
have the greatest diagnostic or prognostic meaning.12 In
keeping with these considerations,11,12 we examined the
metabolic signature of diastolic LV dysfunction in a random
population sample enrolled in the Flemish Study on Environ-
ment, Genes and Health Outcomes (FLEMENGHO).13
Methods
Study Participants
The Ethics Committee of the University of Leuven approved
FLEMENGHO protocol.13 Recruitment started in 1985 and
continued until 2004. The initial participation rate was 78.0%.
Table 1. Characteristics of 711 Participants by Diastolic LV Function Class
Characteristic Normal Abnormal P Value
No. in class 538 173
No. of subjects (%)
Women 262 (48.7) 99 (57.2) 0.051
Smokers 115 (21.4) 29 (16.8) 0.19
Drinking alcohol 391 (72.7) 96 (55.5) <0.0001
Hypertension 158 (29.4) 129 (74.6) <0.0001
Antihypertensive treatment 88 (16.4) 89 (51.5) <0.0001
Diabetes mellitus 5 (1.0) 4 (2.3) 0.16
Mean (SD) of characteristic
Age, y 46.713.8 63.413.2 <0.0001
Body mass index, kg/m2 25.84.0 28.64.5 <0.0001
Waist-to-hip ratio 0.860.08 0.900.08 <0.0001
Office blood pressure, mm Hg
Systolic pressure 125.314.9 140.517.8 <0.0001
Diastolic pressure 79.19.0 81.610.0 0.002
Mean arterial pressure 94.59.9 101.210.2 <0.0001
Heart rate, beats per minute 60.59.0 63.010.9 0.005
Biochemical data
Serum creatinine, lmol/L 82.213.3 87.521.2 0.002
eGFR, mL/min per 1.73 m2 83.416.2 71.814.6 <0.0001
Total cholesterol, mmol/L 5.160.92 5.480.94 0.0001
HDL cholesterol, mmol/L 1.440.36 1.380.35 0.054
Total-to-HDL cholesterol ratio 3.771.02 4.181.06 <0.0001
Plasma glucose, mmol/L 4.860.63 5.201.05 <0.0001
c-Glutamyltransferase, units/L 22 (12–48) 26 (13–53) 0.005
Insulin, pmol/L 33.0 (14.4–71.8) 43.1 (21.5–93.3) <0.0001
NT-proBNP, pmol/L 192 (91–395) 242 (117–493) <0.0001
Diastolic dysfunction includes an abnormally low age-specific transmitral E/A ratio without increased LV filling pressures (E/e’ ≤8.5) or an elevated LV filling pressure (E/e’ >8.5) with
normal or low age-specific E/A (see references 4 and 5). Office blood pressure was the average of 5 consecutive readings. Hypertension was an office blood pressure of ≥140 mm Hg
systolic, or ≥90 mm Hg diastolic, or use of antihypertensive drugs. For c-glutamyltransferase, insulin and NT-proBNP values are geometric mean (interquartile range). NT-proBNP was
measured in 488 and 161 participants in the normal and abnormal LV function group, respectively. Diabetes mellitus was a self-reported diagnosis, a fasting glucose level of at least
7 mmol/L, or use of antidiabetic agents. eGFR indicates estimated glomerular filtration rate derived by the Chronic Kidney Disease Epidemiology Collaboration equation formula; HDL,
high-density lipoprotein; LV, left ventricular; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide;
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Participants were repeatedly followed up.13 From May 2005
until May 2010, we mailed an invitation letter to 1208 former
participants for a follow-up examination. However, 153 were
unavailable because they had died (n=26), had been institu-
tionalized or were too ill (n=27), or had moved out of the area
(n=100). Of the remaining 1055 former participants, 828
renewed informed consent. At the stage of re-examination, the
participation rate was therefore 78.5%. We excluded 117
participants from analysis because serum samples were
unavailable (n=96),metabolites had extreme values dissociated
from the distribution (n=3), atrial fibrillation or paced heart
rhythm made assessment of diastolic LV function impossible
(n=7), or poor echocardiographic image quality (n=11). Thus,
the number of participants statistically analyzed totaled 711.
Echocardiography
Data acquisition
One observer (T.K.) did the ultrasound examination,4 using a
Vivid7 Pro (GE Vingmed, Horten, Norway) device interfacedwith
a 2.5- to 3.5-MHz phased-array probe. For offline analysis, she
recorded at least 5 heart cycles according to the recommen-
dations of the American Society of Echocardiography.14
M-mode echocardiograms of the left ventricle were recorded
from the parasternal long-axis view under control of the
2-dimensional image. The ultrasound beam was positioned just
below the mitral valve at the level of the posterior tendinous
chords. To record mitral and pulmonary vein (PV) flow velocities
from the apical window, the observer positioned the Doppler
sample volume at the mitral valve tips, in the right superior PV,
and between the LV outflow and mitral inflow, respectively.
From the apical window, the observer positioned a 5-mm
Doppler sample at the septal, lateral, inferior, and posterior
sites of the mitral annulus to record low-velocity, high-intensity
myocardial signals at a high frame rate (>190 frames per
second), while ensuring parallel alignment of the ultrasound
beam with the myocardial segment of interest.
Off-line analysis
One reader (T.K.) analyzed the digitally stored images, averag-
ing 3 heart cycles, using a workstation running EchoPac
software (version 4.0.4; GE Vingmed, Horten, Norway). LV
internal diameter and interventricular septal and posterior wall
thickness were measured at end-diastole from the 2-dimen-
sionally guided M-mode tracing. When optimal orientation of
M-mode ultrasound beam could not be obtained, the reader
performed linear measurements on correctly oriented
2-dimensional (2D) images. End-diastolic LV dimensions were
used to calculate LV mass by an anatomically validated
formula.14 Left atrial (LA) volume was calculated using the
prolate-elipsoidmethod from the LA dimensions in 3 orthogonal
planes and indexed to body surface area.14 From the transmitral
flow signal, the reader determined peak early diastolic velocity
(E), peak late diastolic velocity (A), E/A ratio, and transmitral A
flow duration. From the PV flow signal, she measured the
duration of PV reversal flow during atrial systole (AR). From the
tissue Doppler imaging recordings, the reader measured peak
early (e’) and peak late (a’) diastolic mitral annular velocities,
and the e’/a’ ratio at the 4 acquisition sites (septal, lateral,
inferior, and posterior).
Intraobserver reproducibility was the 2-SD interval about
the mean of the relative differences across pair-wise readings.
Intraobserver reproducibility for the tissue Doppler peak
velocities across the 4 sampling sites ranged from 4.5% to
5.3% for e’ and from 4.0% to 4.5% for a’.4 Reproducibility was
2.2% for internal end-diastolic LV diameter, 4.6% for LV wall
thickness, and 4.3% for LV mass.15
We dichotomized diastolic LV function into normal and
abnormal as described in previous publications.4,5 Diastolic
dysfunction included: (1) patients with an abnormally low age-
specific transmitral E/A ratio indicative of impaired relaxation,
but without evidence of increased LV filling pressures (E/e’
≤8.5); (2) patients with mildly to moderately elevated LV filling
pressure (E/e’ >8.5) and an E/A ratio within the normal
age-specific range; and (3) and patients with an elevated E/e’
Table 2. Echocardiographic Measurements by Diastolic LV
Function Class
Characteristic Normal Abnormal
Number in class 538 173
Conventional echocardiography
Left atrial volume, mL 41.212.4 48.115.5
Left atrial volume index, mL/m2 21.95.40 26.07.54
Left ventricular mass, g 166.844.9 194.656.8
Left ventricular mass index, g/m2 88.819.1 104.525.5
Doppler data
Deceleration time, ms 160.231.0 190.244.0
Isovolumetric relaxation time, ms 94.414.0 107.218.6
E peak, cm/s 77.314.9 68.217.2
A peak, cm/s 59.113.9 82.315.7
E/A ratio 1.390.46 0.850.24
e’ peak, cm/s 12.63.26 7.801.95
a’ peak, cm/s 9.782.11 11.11.92
e’/a’ ratio 1.420.66 0.730.26
E/e’ ratio 6.381.35 9.132.74
Diastolic dysfunction includes an abnormally low age-specific transmitral E/A ratio
without increased LV filling pressures (E/e’ ≤8.5) or an elevated LV filling pressure (E/e’
>8.5) with normal or low age-specific E/A (see references 4 and 5). By definition, all P
values for the between-group differences were significant. LV indicates left ventricular.
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ratio and an abnormally low age-specific E/A ratio (combined
dysfunction). To confirm elevation of LV filling pressure, the
reader of the offline echocardiographic images checked the
differences in the duration between the transmitral A flow (Ad)
and the reverse flow in the pulmonary veins (ARd) during atrial
systole (Ad<ARd+10) and the left atrial volume index
(≥28 mL/m2).
Nuclear Magnetic Resonance Spectroscopy
For nuclear magnetic resonance (NMR) spectroscopy,7,16,17
500 lL of plasma were mixed with 50 lL of D2O (as a field
lock). A total of 500 lL of the mixture of each sample was then
individually transferred into a 5-mm high-resolution NMR tube.
All proton NMR (1H NMR) spectra were acquired using a
standard 1-dimensional pulse sequence with water suppres-
sion (Bruker Avance 600 spectrometer operating at
600.13 MHz with a 5-mm 1H/13C/15N TXI probe). A total
of 256 FIDs (free induction decay) were collected into 64 k
data points with a spectral width of 14 ppm and a recycle delay
(RD) of 1 second. The water signal was saturated with weak
irradiation during the RD. Before Fourier transformation, the
FID was multiplied by a 0.3-Hz exponential line broadening.
Spectral chemical shift referencing on the alanine CH3
doublet signal at 1.475 ppm was performed in all spectra.
Resonances in these spectral regions were assigned using the
literature18 and selected 2D NMR (especially for long chain
metabolites) spectra. We normalized all spectra to total
spectral area. Thus, individual peak intensities were normalized
to total metabolite content for a better comparison between
samples. Spectral regions belonging to EDTA resonances
(2.52–2.57 and 3.06–3.17 ppm) were removed from spectra
for subsequent analysis. We used available spectral databases
and 2D NMR experiments to aid structural identification of
relevant metabolites. All spectra were processed using Topspin
1.3 (Bruker Biospin GmbH, Rheinstetten, Germany) and
transferred to MATLAB (2006; The MathWorks, Inc., Natick,
Table 3. List of Plasma Metabolic Biomarkers
Amino Acids 1H Shift
2-Aminobutyrate (C4H9NO2) 1.86
4-Aminobutyrate (C4H9NO2) 3.00
Alanine (C3H7NO2) 1.46
Aspartate (C4H7NO4) 2.81
Glutamate (C5H9NO4) 2.36
Glycine (C2H5NO2) 3.55
Glutamine (C5H10N2O3) 2.42
Isoleucine (C6H13NO2) 1.00
Leucine (C6H13NO2) 1.71
Phenylalanine (C9H11NO2) 3.26
Threonine (C4H9NO3) 3.58
Tyrosine (C9H11NO3) 6.88
Valine (C5H11NO2) 0.97
Lipids 1H Shift
Fatty acids with a-CH2 2.23
Fatty acids with (-CH2-)n 1.25
Fatty acids with =CH-CH2-CH2= +citrate 2.69
Fatty acids with –CH3 0.84
Fatty acids with =CH-CH2-CH2- 2.00
Fatty acids with –CH=CH 5.31
HDL apolipoproteins 6.50
Cholesterol (C27H46O) 0.66
Valerate (C5H10O2) 1.28
Fatty acids with b-CH2 1.57
3-Hydroxybutyrate (C4H8O3) 1.20
Carbohydrates 1H Shift
a-Glucose (C6H12O6) 5.23
Glucose+taurine (C6H12O6+C2H7NO3S) 3.24
Glucose (C6H12O6) 3.47
Glycoprotein 2.04
Organic Acids 1H Shift
Acetate (C2H4O2) 1.91
4-Hydroxybutyrate (C4H8O3) 1.78
Lactate (C3H6O3) 1.33
2-Oxobutyrate (C4H6O3) 2.75
Other Metabolites 1H Shift
Creatinine (C4H7N3O) 4.05
Choline (C5H14NO) 3.21
Ethanolamine (C2H7NO) 3.41
Trimethylamine (C3H9N) 3.37
Glycerol (C3H8O3) 3.61
Continued
Table 3. Continued
Other Metabolites 1H Shift
Ethanol (C2H6O) 3.64
Creatine+creatine-phosphate
(C4H9N3O2+C4H10N3O5P)
3.92
Phosphocholine (C5H15NO4P) 3.22
Glucose+2-aminobutyrate (C6H12O6+C4H9NO2) 3.72
Glucose+glutamine (C6H12O6+C5H10N2O3) 3.78
Glucose+2-phosphoglycerate (C6H12O6+C3H7O7P) 3.80
Unknown molecule 3.87
HDL indicates high-density lipoprotein.
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MA) using in-house scripts for data analysis. Signals belonging
to selected metabolites were integrated and quantified, using
semiautomated in-house MATLAB peak-fitting routines. These
fitting routines were based on Levenburg-Marquard optimiza-
tion procedures. The target function for the optimization
included experimental spectra measured for standard solutions
of selected metabolites with complex multiplet patterns and
theoretically generated Lorentzian-shape signals for those
metabolites with simpler spectral patterns.
Other Measurements
Blood pressure was the average of 5 consecutive auscultatory
readings obtained according to European guidelines with a
standard mercury sphygmomanometer with the participant
resting in the seated position for at least 5 minutes.19
Hypertension was a blood pressure of at least 140 mm Hg
systolic or 90 mm Hg diastolic or use of antihypertensive
drugs. Body mass index (BMI) was weight in kilograms divided
by height in meters squared. Venous blood samples were
drawn after at least 8 hours of fasting for measurement of
plasma glucose and serum total and high-density lipoprotein
(HDL) cholesterol, creatinine, c-glutamyltransferase (biomar-
ker of alcohol intake), and insulin. The homeostatic model
assessment (HOMA) index was computed from glucose and
insulin.20 Glomerular filtration rate (GRF) was derived by the
Chronic Kidney Disease Epidemiology Collaboration equa-
tion.21 Diabetes mellitus was a self-reported diagnosis, a
fasting glucose level of at least 7 mmol/L, or use of
antidiabetic agents.22 In 649 participants, N-terminal of the
prohormone BNP (NT-proBNP) was measured in plasma by a
Table 4. Levels of Metabolic Biomarkers by Diastolic LV
Function Class
Metabolic Biomarker
Normal
(n=538)
Abnormal
(n=173) P Value
Amino acids
2-Aminobutyrate 17.71.09 17.40.82 0.0003
4-Aminobutyrate 6.970.50 6.800.50 0.0001
Alanine 12.30.63 12.20.51 0.0058
Aspartate 5.460.73 5.460.58 0.95
Glutamate 9.261.12 9.060.77 0.0088
Glycine 1.280.16 1.290.16 0.62
Glutamine 10.41.48 10.21.18 0.018
Isoleucine 12.60.59 12.50.57 0.075
Leucine 33.42.51 32.71.86 0.0002
Phenylalanine 2.920.62 2.910.58 0.83
Threonine 2.310.27 2.350.24 0.098
Tyrosine 2.360.35 2.290.25 0.0045
Valine 9.650.46 9.510.46 0.0009
Lipids
Fatty acids with a-CH2 10.60.89 10.80.78 0.0057
Fatty acids with (-CH2-)n 51.26.59 51.35.51 0.81
Fatty acids with =CH-CH2-
CH2= +citrate
16.71.89 17.01.34 0.019
Fatty acids with –CH3 64.86.83 64.24.52 0.20
Fatty acids with =CH-
CH2-CH2-
36.11.23 36.01.09 0.52
Fatty acids with –CH=CH 11.12.62 11.82.42 0.0016
HDL apolipoproteins 46.06.96 44.65.65 0.0099
Cholesterol 22.64.88 21.92.73 0.012
Valerate 35.77.91 38.58.03 <0.0001
Fatty acids with b-CH2 39.72.00 39.71.22 0.75
3-Hydroxybutyrate 18.42.30 18.53.59 0.82
Carbohydrates
a-Glucose 2.270.42 2.390.56 0.010
Glucose+taurine 9.311.21 9.261.19 0.61
Glucose 20.22.18 20.62.67 0.048
Glycoprotein 15.50.79 15.91.09 0.0003
Organic acids
Acetate 5.360.31 5.290.42 0.037
4-Hydroxybutyrate 16.01.29 15.60.91 <0.0001
Lactate 13.72.49 14.72.47 <0.0001
2-Oxobutyrate 4.670.62 4.830.49 0.0006
Other metabolites
Creatinine 2.840.21 2.830.16 0.26
Choline 3.311.09 3.210.38 0.055
Continued
Table 4. Continued
Metabolic Biomarker
Normal
(n=538)
Abnormal
(n=173) P Value
Ethanolamine 0.810.15 0.830.13 0.89
Trimethylamine 0.550.13 0.540.12 0.45
Glycerol 1.910.38 1.910.16 0.72
Ethanol 4.550.52 4.520.38 0.50
Creatine+creatine-
phosphate
1.490.14 1.470.12 0.027
Phosphocholine 6.501.09 6.171.05 0.0006
Glucose+2-aminobutyrate 6.160.57 6.290.73 0.044
Glucose+glutamine 6.080.56 6.160.53 0.11
Glucose+2-
phosphoglycerate
1.420.13 1.430.13 0.31
Unknown molecule 3.560.31 3.550.29 0.55
Diastolic dysfunction includes an abnormally low age-specific transmitral E/A ratio
without increased LV filling pressures (E/e’ ≤8.5) or an elevated LV filling pressure (E/e’
>8.5) with normal or low age-specific E/A (see references 4 and 5). P values denote the
significance of the differences between groups. LV indicates left ventricular.
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competitive enzyme immunoassay (EIA) for research use
(Biomedica Gruppe, Vienna, Austria).
Statistical Analysis
For database management and statistical analysis, we used the
SAS system (version 9.3; SAS Institute Inc., Cary, NC). Means
were compared using the large-sample z-test or ANOVA and
proportions by Fisher’s exact test. We normalized the distri-
butions of c-glutamyltransferase, insulin, and NT-proBNP by a
logarithmic transformation. Our statistical methods also
included multivariable linear regression with, as dependent
variables, the echocardiographic indexes of diastolic LV
function. We identified variables to be retained in the analyses
by a step-wise regression procedure with P value for variables
to enter and stay in the models set at 0.15. Statistical
significance was a 2-sided P level of 0.05. Where appropriate,
we applied Bonferroni correction for multiple testing by
multiplying P values by 44 (the number of metabolites tested).
The annotation P and PB refer to significance levels unadjusted
and adjusted for multiple testing.
We constructed a log10 probability plot for the multivari-
able-adjusted associations of the diastolic LV function indexes
with the metabolites. In the next step of our analyses, we
dichotomized the study population in 538 participants with
normal LV function and in 173 with subclinical diastolic LV
dysfunction4,5 and used a binary dummy variable indicating
membership to these 2 groups as a dependent variable in a
partial least squares discriminant analysis (PLS-DA) to identify
a set of independent latent factors (LFs) that were linear
combinations of the metabolites and that maximized the
covariance between the metabolites and LV diastolic dysfunc-
tion. We retained the smallest number of latent factors for
which the predicted residual sums of squares (PRESS;
calculated using leave-one-out cross-validation) did not differ
significantly (P>0.10) from the model with the minimum PRESS
value as assessed by the van der Voet T2 statistic. The
importance of each metabolite in the construction of the PLS
factors was assessed from the Variable Importance in Projec-
tion (VIP) scores of Wold.
Finally, we evaluated the capability of the LFs to discriminate
between participants with and without diastolic LV dysfunction
by constructing the receiver operating characteristic (ROC)
curve and by calculating the area under the ROC curve (AUC).
The 95% CI of the AUCwas calculated by the DeLongmethod.23
The discriminative capability of the latent factors on top of
NT-proBNP was assessed by comparing the AUCs from a basic
model including NT-proBNP and an extended model including
NT-proBNP plus the LFs. We tested the statistical significance
of the change in AUC attributable to adding the LFs to
NT-proBNP by the Delong test for paired ROC curves.23
Results
Characteristics of Participants
Of 711 participants, 361 (50.8%) were women. All subjects
were white Europeans. Mean values (SD) in all participants
Table 5. Covariates Selected by Step-wise Regression
Variables E Peak A Peak E/A e’ a’ e’/a’ E/e’
R2 0.27 0.68 0.66 0.75 0.50 0.72 0.46
Female sex (0, 1) 9.284§ 5.944§ — 0.354† 0.950§ 0.078‡ 1.109§
Age (+15.4 y) 6.478§ 9.972§ 0.316§ 2.380§ 1.248§ 0.453§ 0.811§
Body mass index (+4.3 kg/m2) — 3.188§ 0.077§ 0.630§ 0.385§ 0.138§ 0.291§
Mean arterial pressure (+10.4 mm Hg) — 1.943§ 0.024† 0.308§ — 0.035† 0.320§
Heart rate (+9.6 bpm) 3.085§ 3.554§ 0.131§ 0.252§ 0.689§ 0.117§ 0.122*
Total cholesterol (+0.95 mmol/L) 1.127† — 0.029‡ 0.200‡ 0.173‡ 0.063§ —
Log c-glutamyltransferase (92) — 5.843* — 2.571§ 0.938* 0.290† —
Fasting plasma glucose (+0.77 mmol/L) 0.835* — — 0.115* — — 0.109*
LVMI (+21.9 g/m2) — — — 0.332§ 0.237‡ — 0.360§
On treatment with diuretics (0, 1) — — — 0.452* 0.420* — 0.932§
On treatment with b-blockers (0, 1) — 2.302* 0.068† 0.457† 0.698§ — —
On treatment with RAAS inhibitors (0, 1) 4.858† — — — — — 0.495†
Variables considered for entry into the models included sex, age, body mass index, mean arterial pressure, heart rate, total cholesterol, c-glutamyltransferase (as index of alcohol intake),
fasting plasma glucose, LVMI, and treatment with diuretics (thiazides, loop diuretics and aldosterone antagonists), b-blockers, inhibitors of the renin-angiotensin system (angiotensin-
converting enzyme inhibitors or angiotensin type-1 receptor blockers), and vasodilators (calcium-channel blockers and a-blockers). P values for variables to enter and stay in the regression
models were set at 0.15. LVMI left ventricular mass index; RAAS, renin-angiotensin-aldosterone system.
Significance of the association: *0.05<P≤0.15; †P≤0.05; ‡P≤0.01; §P≤0.001.
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combinedwere 50.8 (15.4) years for age, 129.0 (17.0) and 79.7
(9.3)mm Hg for systolic and diastolic blood pressure, 26.5 (4.3)
kg/m2 for BMI, and 5.24 (0.95) mmol/L for total cholesterol. Of
all participants, 287 (40.4%) had hypertension, of whom 177
(61.7%) were on antihypertensive drug treatment, and 9 (1.3%)
had diabetes. The prevalence of diastolic LV dysfunction
amounted to 173 (24.3%), because of impaired relaxation in
70 (40.5%) or an elevated filling pressure in the presence of a
normal (79 [45.7%]) or low (24 [13.9%]) age-specific E/A ratio.
Associations of Diastolic LV Function With
Metabolites
Unadjusted analyses
Comparing with participants with normal function (Table 1),
age, BMI, central obesity, blood pressure, heart rate, serum
creatinine, c-glutamyltransferase and insulin, plasma glucose,
total-to-HDL cholesterol ratio, and NT-proBNP all increased
(P≤0.005), whereas estimated GFR (eGFR) decreased
(P<0.0001), in participants with diastolic LV dysfunction.
Table 2 shows that LA volume, LA volume index, LV mass, LV
mass index (LVMI), deceleration time, isovolumetric relaxation
time, A and a’ peak velocities, and E/e’ ratio increased
(P<0.0001) in participants with diastolic LV dysfunction,
whereas the opposite was the case (P<0.0001) for E and e’
peak velocities and the E/A and e’/a’ ratios. Table 3 lists the
circulating metabolites subdivided into amino acids, lipids,
carbohydrates, organic acids, and other molecules. Table 4
shows that of 44 non-overlapping metabolites, 24 showed
significant differences between 2 groups. Generally, amino
acids were lower in diastolic LV dysfunction group (8 of 8
significant associations), whereas fatty acids were higher (4 of
6 significant associations).
Multivariable-adjusted regression
Variables considered for entry and retained for multivariable
adjustment of the indexes of diastolic LV function are listed in
Figure 1. –Log10(P) probability plot of the multivariable-adjusted
associations of various indexes of diastolic left ventricular
dysfunction (see Table 6) with the metabolic biomarkers. TYR,
HDL_A, GLC_TAU, PHC, GLC_AB, GLC_GLN, GLC_PG, and UN,
respectively, indicate tyrosine, high-density lipoprotein apolipopro-
teins, glucose+taurine, phosphocholine, glucose+2-aminobutyrate,
glucose+glutamine, glucose+2-phosphoglycerate, and unknown
molecule. The adjustment accounted for sex, age, body mass
index, mean arterial pressure, heart rate, total cholesterol,
c-glutamyltransferase, fasting plasma glucose, treatment with
diuretics, b-blockers, and inhibitors of the renin-angiotensin
system. The horizontal line denotes the significance level with
Bonferroni correction applied.
Table 6. Multivariable-Adjusted Associations of Tissue
Doppler indexes With Metabolites
Metabolic Markers (SD) Estimate (95% CI) PB Value
Tyrosine (0.327)
a’ peak 0.225 (0.419, 0.030) 0.009
e’/a’ 0.054 (0.010, 0.099) 0.004
HDL apolipoproteins (6.689)
a’ peak 0.229 (0.425, 0.034) 0.004
e’/a’ 0.050 (0.005, 0.095) 0.013
Glucose+taurine (1.209)
e’ peak 0.250 (0.005, 0.496) 0.044
Phosphocholine (1.091)
e’ peak 0.255 (0.003, 0.507) 0.044
Glucose+2-aminobutyrate (0.616)
a’ peak 0.261 (0.509, 0.014) 0.026
Glucose+glutamine (0.552)
a’ peak 0.277 (0.483, 0.070) 0.0007
e’/a’ 0.049 (0.001, 0.097) 0.035
Glucose+2-phosphoglycerate (0.131)
a’ peak 0.209 (0.407, 0.010) 0.031
Unknown molecule (0.307)
a’ peak 0.203 (0.404, 0.002) 0.048
e’/a’ 0.047 (0.001, 0.093) 0.044
All estimates were adjusted for sex, age, body mass index, mean arterial pressure, heart
rate, total cholesterol, c-glutamyltransferase, plasma glucose, LV mass index, and
treatment with diuretics, b-blockers, and inhibitors of the renin-angiotensin system.
Estimates express the change in the dependent variable for a 1-SD increase in circulating
metabolites. P values and 95% CIs account for testing 44 metabolites according to the
Bonferroni approach. HDL indicates high-density lipoprotein; LV, left ventricular.
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Table 5. We adjusted the associations of the indexes of
diastolic LV function for sex, age, BMI, mean arterial pressure,
heart rate, total cholesterol, c-glutamyltransferase, plasma
glucose, LVMI and treatment with diuretics, b-blockers, and
inhibitors of the renin-angiotensin system and applied Bon-
ferroni correction of the significance levels. Under these
conditions, the transmitral blood flow Doppler indexes were
not correlated with any circulating metabolite. There was a
positive correlation of e’ peak velocity with glucose+taurine
and phosphocholine (Figure 1; PB=0.044 for both). Signifi-
cance was also preserved (Figure 1) for the negative corre-
lations of a’ peak velocity with tyrosine, HDL apolipoproteins,
glucose+2-aminobutyrate, glucose+glutamine, glucose+2-
phosphoglycerate, and an unknown molecule (PB≤0.048)
and the positive correlations of e’/a’ with tyrosine, HDL
apolipoproteins, glucose+glutamine, and an unknown mole-
cule (PB≤0.044). Table 6 lists quantitative estimates for the
association sizes expressing the differences in the diastolic LV
function indexes per 1-SD increment in the circulating
metabolites with 95% CIs rescaled to the Bonferroni signif-
icance level. The results reported in Figure 1 and Table 6
remained consistent, if models were additionally adjusted for
insulin or if glucose was replaced by the HOMA index.20
However, additional adjustment for HDL cholesterol or
replacing total cholesterol by the total-to-HDL cholesterol
ratio removed the significance of the associations of e’ peak
velocity with glucose+taurine and phosphocholine.
Partial Least Square Discriminant Analysis
We dichotomized the study population in 538 participants
with normal LV function and in 173 with subclinical diastolic
LV dysfunction.4,5 The PLS-DA procedure identified 3 latent
factors accounting for 19.5%, 21.3%, and 13.6% of the
Table 7. Factor Loadings of the Metabolic Biomarkers in
Analyses Contrasting Normal With Diastolic LV Dysfunction
Metabolic Biomarker LF1 LF2 LF3
Amino acids
2-Aminobutyrate 0.25 0.13 0.10
4-Aminobutyrate 0.23 0.16 0.14
Alanine 0.26 0.04 0.03
Aspartate 0.02 0.15 0.27
Glutamate 0.13 0.15 0.26
Glycine 0.07 0.23 0.01
Glutamine 0.13 0.16 0.27
Isoleucine 0.11 0.11 0.12
Leucine 0.24 0.13 0.12
Phenylalanine 0.01 0.16 0.26
Threonine 0.08 0.26 0.02
Tyrosine 0.15 0.06 0.05
Valine 0.18 0.13 0.13
Lipids
Fatty acid with a-CH2 0.21 0.01 0.21
Fatty acid with (-CH2-)n 0.12 0.21 0.14
Fatty acid with =CH-CH2-CH2= +citrate 0.01 0.14 0.23
Fatty acid with –CH3 0.03 0.19 0.24
Fatty acid with =CH-CH2-CH2- 0.05 0.18 0.10
Fatty acid with –CH=CH 0.24 0.07 0.07
HDL apolipoproteins 0.15 0.08 0.08
Cholesterol 0.08 0.12 0.27
Valerate 0.31 0.10 0.05
Fatty acid with b-CH2 0.05 0.02 0.22
3-Hydroxybutyrate 0.01 0.13 0.25
Carbohydrates
a-glucose 0.11 0.07 0.05
Glucose+taurine 0.06 0.05 0.07
Glucose 0.04 0.26 0.02
Glycoprotein 0.19 0.09 0.04
Organic acids
Acetate 0.25 0.08 0.06
4-Hydroxybutyrate 0.25 0.10 0.13
Lactate 0.28 0.03 0.12
2-Oxobutyrate 0.13 0.08 0.23
Other metabolites
Creatinine 0.01 0.15 0.24
Choline 0.06 0.03 0.04
Ethanolamine 0.10 0.16 0.08
Trimethylamine 0.01 0.14 0.18
Continued
Table 7. Continued
Metabolic Biomarker LF1 LF2 LF3
Glycerol 0.09 0.16 0.04
Ethanol 0.14 0.14 0.12
Creatine+creatine-phosphate 0.15 0.21 0.14
Phosphocholine 0.14 0.08 0.01
Glucose+2-aminobutyrate 0.03 0.23 0.12
Glucose+glutamine 0.10 0.28 0.02
Glucose+2-phosphoglycerate 0.13 0.24 0.09
Unknown molecule 0.14 0.22 0.06
The study population was dichotomized in 538 participants with normal LV function
and 173 with subclinical diastolic LV dysfunction.4,5 LF1, LF2, and LF3 refer to the
first, second, and third latent factors derived by partial least square discriminant
analysis of 44 metabolites. LV indicates left ventricular.
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variance in the metabolites and 54.4% in total. Table 7
presents the factor loadings of the circulating metabolites on
LF1, LF2, and LF3. As listed in Table 8, metabolites with a VIP
score greater than 1 included phosphocholine (1.142),
glucose+2-aminobutyrate (1.185), glucose+glutamine (1.201),
and glucose+2-phosphoglycerate (1.172), but not tyrosine
(0.808), HDL apolipoproteins (0.806), glucose+taurine
(0.265), and unknown molecule (0.733). Figure 2 shows
the V-plot for the PLS-DA-derived VIP scores versus the
centered and rescaled correlation coefficients. The depen-
dent variable in this analysis was diastolic LV dysfunction.
The metabolites associated with normal diastolic LV function
(left side of the V-plot in Figure 2) included, among others,
glucose+glutamine, glucose+2-aminobutyrate, and glu-
cose+2-phosphoglycerate. Metabolites siding with abnormal
diastolic LV function (right side of the V-plot in Figure 2)
encompassed 4-aminobutyrate, 4-hydroxybutyrate, crea-
tinine, and phosphocholine.
Receiver Operating Curves
Measurement of NT-proBNP in plasma is currently the
standard in diagnosing LV dysfunction and monitoring its
treatment. Figure 3 shows that combining the 3 latent
factors identified by PLS-DA to NT-proBNP increased
(P<0.0001) the AUC from 0.64 (95% CI, 0.58–0.68) to
0.73 (0.68–0.78).
Discussion
In the current study, we applied 2 different methods to
investigate association of diastolic LV function with circulating
metabolites. In multivariable-adjusted regression models with
Bonferroni correction of significance levels applied, a’ was
inversely and e’/a’ was positively correlated with circulating
tyrosine, HDL apolipoproteins, glucose+glutamine, and an
unknown molecule, whereas a’ was also inversely associated
Figure 2. After dichotomizing the study population in 538
participants with normal LV function and 173 with subclinical
diastolic LV dysfunction, V-plots were generated for the PLS-DA-
derived VIP scores versus the centered and rescaled correlation
coefficients. Spots indicating metabolites with a VIP score higher
than 1.1 were labeled. Spots associated with normal diastolic LV
function (left), ordered by descending VIP score include lactate
(LAC), glycoprotein (GLP), valerate (VAC), alanine (ALA), glu-
cose+glutamine (GLC-GLN), glucose (GLC), glucose+2-aminobuty-
rate (GLC-AB), glucose+2-phosphoglycerate (GLC-PG), acetate
(ACT), threonine (THR), and fatty acid with –CH=CH (FAU2). Spots
associated with diastolic LV dysfunction (right), ordered by
ascending VIP score, include leucine (LEU), 2-aminobutyrate
(AB2), phosphocholine (PHC), valine (VAL), 4-hydroxybutyrate
(GHB), creatinine (CRT), and 4-aminobutyrate (AB4). LV indicates
left ventricular; PLS-DA, partial least square discriminant analysis;
VIP, Variable Importance in Projection.
Table 8. VIP Scores in Analyses Contrasting Normal With
Diastolic LV Dysfunction
Metabolomic Biomarker VIP Score
Lactate 1.433
4-Aminobutyrate 1.411
Glycoprotein 1.403
Valerate 1.398
Creatinine 1.271
4-Hydroxybutyrate 1.269
Alanine 1.267
Valine 1.247
Glucose+glutamine 1.201
Glucose 1.187
Glucose+2-aminobutyrate 1.185
Glucose+2-phosphoglycerate 1.172
Acetate 1.143
Phosphocholine 1.142
Threonine 1.126
2-Aminobutyrate 1.112
Leucine 1.112
Fatty acid with –CH=CH 1.106
2-Oxobutyrate 1.027
Fatty acid with a–CH2 1.024
Creatine+creatine-phosphate 1.024
a-Glucose 1.007
Variable Importance in Projection (VIP) scores estimate the importance of each variable
in the projection used in a partial least square (PLS) model and is often used for variable
selection. A variable with a VIP score greater than 1 can be considered important in a
given model. LV indicates left ventricular.
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with glucose+2-aminobutyrate and glucose+2-phosphoglyce-
rate (Table 6). In PLS-DA, metabolites associated with normal
diastolic LV function included glucose+glutamine, glucose+2-
aminobutyrate, and glucose+2-phosphoglycerate, whereas
those siding with abnormal function encompassed 4-amino-
butyrate, 4-hydroxybutyrate, creatinine, and phosphocholine
(Figure 2).
In multivariable-adjusted regression analyses (Table 6), the
early diastolic e’ peak was positively associated with
glucose+taurine and with phosphocholine. The late diastolic
a’ peak velocity, either as single measurement or as
denominator in the e’/a’ ratio, was the other trait associated
with the circulating metabolites. Impaired relaxation, as
reflected by the early diastolic e’ peak velocity, is usually
the first step in the progression toward diastolic LV dysfunc-
tion, but it is also part of the normal aging process.4,5
Stiffening of the LV occurs later and requires a greater
contribution of the atrial contraction to late diastolic LV filling.
This might explain why, in multiple linear regression, fewer
metabolites were associated with e’ than a’. This interpreta-
tion is also in keeping with the observation that in our study
population, in contrast to hospitalized patients with end-stage
HF, only 11 participants, all with high LV filling pressure, had
an e’/a’ ratio higher than unity.
Extruding calcium from cardiomyocytes during early diastole
to facilitate cardiac relaxation and diastolic filling requires high
amounts of energy.24 Higher availability of energy substrate
might improve LV relaxation and reduce the atrial contribution
to LV filling. Glucose+2-phosphoglycerate and glucose+glu-
tamine, 2 metabolic markers involved in the generation of
energy, were associated with lower a’ peak velocity (Figure 1
and Table 6) and better diastolic LV function (Figure 2). As
shown in Figure 4, 2-phosphoglycerate is an intermediate
metabolite in the cytosolic anaerobic glycolysis pathway, which
converts 1 glucosemolecule into 2 pyruvatemoieties, with a net
production of ATP.25 This pathway also generates reduced
NADH. Transferred to mitochondria, NADH links the citric acid
cycle to oxidative phosphorylation, the major source of ATP.25
Oxygen being available, pyruvate produced by glycolysis is
converted to acetyl-CoA (coenzyme A) and runs through the
citric acid cycle, in which acetyl-CoA is completely oxidized
generating ATP through oxidative phosphorylation. Glutamine is
an alternative substrate (Figure 4) that, in the presence of
glucose, can enter the citric acid cycle and generates energy by
aerobic oxidation.26
The antioxidant, glutathione (GSH), is the main hepatic
protection system against systemic oxidative stress.27 When
hepatic availability of cysteine is limited and GSH is depleted,
2-aminobutyrate enters an alternative pathway driven by the
same enzymes leading to the synthesis of ophthalmate.27,28 In
our current study, a performant diastolic function, as exem-
plified by lower a’ peak in the multivariable-adjusted regression
analysis (Table 6) or a VIP-to-correlation-coefficient spot
associated with normal diastolic LV function (left side of the
V-plot in Figure 2) was associated with a higher glucose+2-
aminobutyrate signal. In multivariable-adjusted regression
analyses (Table 6), the early diastolic e’ peak correlated
positively with glucose+taurine and the e’/a’ ratio with HDL
apolipoproteins, whereas the late diastolic a’ peak was
inversely related to tyrosine and HDL apolipoproteins. Protec-
tion against oxidative stress might underlie better diastolic LV
function associated with these 2 markers reflecting amino
acid (tyrosine) and lipid (HDL apolipoproteins) metabolism
(Figure 4). Major sources of the amino acid, taurine, are
hepatic biosynthesis from cysteine and dietary intake.29
Although the underlying mechanisms require further elucida-
tion, several studies suggest that taurine inhibits the gener-
ation of ROS.29 Japanese studies,30 confirmed by other
investigators,31,32 demonstrated that daily taurine administra-
tion to HF patients improved end-diastolic LV volume,31 key
symptoms,30 and exercise capacity.32 Tyrosine, a product of
phenylalanine degradation, is a precursor of dopamine and
melanin.33 At the start of the pathway, phenylalanine upreg-
ulates expression and activity of guanosine-50-triphosphate
cyclohydrolase I, which is the first and rate-controlling enzyme
for synthesis of tetrahydrobiopterin, an essential cofactor for
nitric oxide (NO) synthase and NO synthesis.34 Near the end
of the tyrosine chain, dopamine and melanin reduce the
Figure 3. Receiver operating characteristic (ROC) curves for
discriminating between normal and abnormal diastolic LV function
using NT-proBNP (red line) or NT-proBNP plus 3 latent factors
identified by PLS-DA (green line). Combining the 3 latent factors
with NT-proBNP increased (P<0.0001) the AUC from 0.64 to 0.73.
AUC indicates area under the curve; LV, left ventricular; NT-proBNP,
N-terminal of the prohormone brain natriuretic peptide; PLS-DA,
partial least square discriminant analysis.
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synthesis of proinflammatory cytokines, including tumor
necrosis factor alpha and interleukins 1b, 6, and 10, and
induce production of anti-inflammatory mediators by leuco-
cytes.34 Apolipoprotein (Apo) A1 and apoA2 are the major
protein component of HDL lipoproteins and account for over
two thirds of the protein content of HDL. Both HDL lipopro-
teins and HDL cholesterol possess anti-inflammatory and -
adhesive properties.35 Adjustment for HDL cholesterol or the
total-to-HDL cholesterol ratio in the multivariable-adjusted
regression analysis did not remove the associations of a’ and
e’/a’ with HDL apolipoproteins.
Phospholipid bilayers, in which phosphatidylcholine is the
main constituent, maintain the structure and functionality of
cellular membranes. Phosphocholine is an intermediate
metabolite in the cytidine diphosphocholine pathway that
synthesizes phosphatidylcholine from choline (Figure 4), an
essential nutrient primarily provided by the diet. Carnitine is a
chemical analog of choline and mediates the transport of long-
chain fatty acids into the mitochondrial matrix for beta-
oxidation and has proven antioxidant and -inflammatory
activity. In contrast, choline deficiency is associated with
increased oxidative stress.36 Compared to controls, patients
with diastolic HF have lower serum concentrations of phos-
phatidylcholines.37 L-carnitine is a nutritional supplement
approved by regulatory agencies for use in cardiovascular and
cardiac disease, including HF.38 In multiple linear regression, e’
increased with higher circulating phosphocholine, but in the
PLS-DA, that relied on various Doppler velocities other than e’,
the VIP-to-correlation-coefficient spot (right side of the V-plot in
Figure 2) was associated with diastolic LV dysfunction. Adjust-
ment for HDL-cholesterol or the total-to-HDL cholesterol ratio
weakened the positive association of e’ with phosphocholine in
the multivariable-adjusted regression analysis, perhaps
because HDL-lipoproteins are acceptors in the efflux of
phospholipids and free cholesterol from peripheral cells.35
Strong points of our study are the availability of Doppler
indexes of early subclinical diastolic LV dysfunction, applica-
tion of 2 different approaches in the statistical analysis, and
the population-based character of our research. The epidemi-
ological angle enhances the relevance of our findings over and
beyond that of case-control studies involving selected HF
patients who represent the end stage of a long pathogenetic
process confounded by multiple comorbidities and polymed-
ication.11 However, our present study must also be inter-
preted within the context of its limitations. First, our findings
originate from a cross-sectional analysis and therefore reflect
a snapshot of a long-lasting process in each individual
participant. Moreover, the pathogenetic drivers leading to
Figure 4. Simplified representation of metabolic pathways potentially involved in diastolic LV
dysfunction. Metabolites significantly associated with diastolic LV function are in red color. Depicted
cycles are (A) glycolysis; (B) citric acid (Krebs) cycle; (C) biopterin cycle; (D) 5-methylthioadenosine/
methionine cycle; (E) transsulfuration (taurine); and (F) methylation (phosphatdylcholine). BH2 and BH4
indicate dihydrobiopterin and tetrahydrobiopterin, respectively; CoA, coenzyme A; LV, left ventricular.
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diastolic LV dysfunction are multifaceted, each with different
contributions among people at risk. Whether or not the
metabolic markers can predict the course, over time, of
diastolic LV dysfunction and associated cardiovascular com-
plications remains to be proven in longitudinal studies.
Second, keeping in mind the redundancy and bidirectionality
in many metabolic pathways,25 studies like ours cannot
determine whether levels of circulating metabolites vary
because of changes in production or degradation or release
into or clearance from the circulation, or because of a
combination of these mechanisms. Third, epidemiological
studies only demonstrate association. Our proposal of
molecular pathways (Figure 4) linking diastolic LV dysfunction
to the metabolic markers rests on our interpretation of the
available literature. Fourth, our findings need replication in
other cohorts and validation in molecular studies. Finally,
NMR spectroscopy is fast and keeps samples separated from
the instrument, but produces crowded spectra that cannot
always be reliably deconvoluted to single metabolites.16
Conclusions
In this first population study of its kind, we identified a profile of
circulating metabolites, indicative of energy substrate utilization
and protection against oxidative stress, associated with diastolic
LV function. In ROC curve analyses, adding the LFs toNT-proBNP
increased the AUC. Given the current state of this newly
emerging field of research, we believe that, in the near future, the
principal application of metabolic markers might lie in the
characterization of biochemical pathways leading to diastolic LV
dysfunction rather than in diagnosing this condition. One line of
research that we are currently pursuing in this respect is linking
the metabolic profiles to markers of mitochondrial function.39
Deeper insights in the pathogenetic mechanisms causing
diastolic HF will potentially identify new targets for prevention
and treatment at a subclinical and still reversible stage.
Acknowledgments
Thibault Petit, MD, Yu-Mei Gu, MD, Judita Knez, MD, Nicholas
Cauwenberghs, MSc, collected data at the field center of the Flemish
Study on Environment, Genes and Health Outcomes (Eksel, Belgium)
and Azusa Hara, PhD helped with database construction and end
point validation at the Studies Coordinating Centre, Leuven, Belgium.
The authors gratefully acknowledge the clerical assistance of R.
Wolfs and the technical support of L. Custers, M.J. Jehoul, D. Thijs
and H. Truyens in data collection.
Sources of Funding
The European Union (grants HEALTH-2011.2.4.2-2-EU-MAS-
CARA, HEALTH-F7-305507 HOMAGE, and the European
Research Council Advanced Researcher Grant-2011-294713-
EPLORE) gave support to the Studies Coordinating Centre
(Leuven, Belgium). The Fonds voor Wetenschappelijk Onder-
zoek Vlaanderen, Ministry of the Flemish Community (Brus-
sels, Belgium; G.0881.13, G.0880.13, and 11Z0916N) also
supported the FLEMENGHO study.
Disclosures
None.
References
1. Paulus WJ, Tsch€ope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers
FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I,
Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG,
Brutsaert DL. How to diagnose heart failure: a consensus statement on the
diagnosis of heart failure with normal left ventricular ejection fraction by the
Heart Failure and Echocardiography Associations of the European Society of
Cardiology. Eur Heart J. 2007;28:2539–2550.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata
DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM,
Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT,
Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB,
McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP,
Schreiner PJ, Sorlie PD, Stein J, Turan TN, Varani SS, Wong ND, Woo D, Turner
MB; American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Heart disease and stroke statistics—2013 update: a report
from the American Heart Association. Circulation. 2013;121:e6–e245.
3. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction:
pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670–679.
4. Kuznetsova T, Herbots L, Lopez B, Jin Y, Richart T, Thijs L, Gonzalez A,
Herregods MC, Fagard RH, Dıez J, Staessen JA. Prevalence of left ventricular
diastolic dysfunction in a general population. Circ Heart Fail. 2009;2:105–112.
5. Kloch-Badelek M, Kuznetsova T, Sakiewicz W, Tikhonoff V, Ryabikov A,
Gonzalez A, Loster M, Thijs L, Jin Y, Malyutina S, Stolarz-Skrzypek K, Casiglia E,
Dıez J, Narkiewicz K, Kawecka-Jaszcz K, Staessen JA; on behalf of the European
Project on Genes in Hypertension (EPOGH) Investigators. Prevalence of
diastolic left ventricular dysfunction in European populations based on cross-
validated diagnostic thresholds. Cardiovasc Ultrasound. 2012;10:10.
6. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer
RJ. Burden of systolic and diastolic ventricular dysfunction in the community.
Appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–
202.
7. Marrachelli VG, Monleon D, Rentero P, Mansego ML, Morales JM, Galan I,
Segura R, Martinez F, Martin-Escudero JC, Briongos L, Marin P, Lliso G, Chaves
FJ, Redon J. Genomic and metabolomic profile associated to microalbuminuria.
PLoS One. 2014;9:e98227.
8. Cheng ML, Wang CH, Shiao MS, Liu MH, Huang YY, Huang CY, Mao CT, Lin JF,
Ho HY, Yang NI. Metabolic disturbances identified in plasma are associated
with outcomes in patients with heart failure: diagnostic and prognostic value of
metabolomics. J Am Coll Cardiol. 2015;65:1509–1520.
9. Tenori L, Hu XY, Pantaleo P, Alterini B, Casttelli G, Olivotto L, Bertini I, Luchinat
C, Gensini GF. Metabolomic fingerprint of heart failure in humans: a nuclear
magnetic resonance spectroscopy analysis. Int J Cardiol. 2013;168:e113–
e115.
10. Kang SM, Park JC, Shin MJ, Lee H, Oh J, Ryu DH, Hwang GS, Chung JH. 1H
nuclear magnetic resonance based metabolic urinary profiling of patients with
ischemic heart failure. Clin Biochem. 2011;44:293–299.
11. Wang TJ, Gupta DK. Metabolic profiles in heart failure. Looking for unique
signatures in a heterogeneous syndrome. J Am Coll Cardiol. 2015;65:1521–
1524.
12. Zhang Z, Staessen JA, Thijs L, Gu Y, Liu Y, Jacobs L, Koeck T, Z€urbig P, Mischak
H, Kuznetsova T. Left ventricular diastolic dysfunction in relation to the urinary
proteome: a proof-of-concept study in a general population. Int J Cardiol.
2014;176:158–165.
13. Liu YP, Gu YM, Thijs L, Knapen MHJ, Salvi E, Citterio L, Petit T, Delli Carpini S,
Zhang Z, Jacobs L, Jin Y, Barlassina C, Manunta P, Kuznetsova T, Verhamme P,
Struijker-Boudier HA, Cusi D, Vermeer C, Staessen JA. Inactivematrix Gla protein
is causally related to adverse health outcomes: aMendelian randomization study
in a Flemish population. Hypertension. 2015;65:463–470.
DOI: 10.1161/JAHA.115.002681 Journal of the American Heart Association 12
Diastolic LV Function and Metabolic Biomarkers Zhang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at KU Leuven University Library on April 12, 2016http://jaha.ahajournals.org/Downloaded from 
14. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead
A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ. American
Society of Echocardiography recommendations for use of echocardiography in
clinical trials. A report from the American Society of Echocardiography’s
Guidelines and Standard Committee and the Task Force on Echocardiography
in Clinical Trials. J Am Soc Echocardiogr. 2004;17:1086–1119.
15. Kuznetsova T, Codd V, Brouilette S, Thijs L, Gonzalez A, Jin Y, Richart T, van der
Harst P, Dıez J, Staessen JA, Samani NJ. Association between left ventricular
mass and telomere length in a population study. Am J Epidemiol.
2010;172:440–450.
16. Griffin JL, Atherton H, Shockcor J, Atzori L. Metabolomics as a tool for cardiac
research. Nat Rev Cardiol. 2011;8:630–643.
17. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification
of novel biomarkers and mechanisms related to common cardiovascular
diseases: form and function. Circulation. 2012;126:1110–1120.
18. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and
1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67:
793–811.
19. O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers
M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G,
Verdecchia P; on behalf of the European Society of Hypertension Working
Group on Blood Pressure Monitoring. European Society of Hypertension
recommendations for conventional, ambulatory and home blood pressure
measurement. J Hypertens. 2003;21:821–848.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasis model assessment: insulin resistance and b-cell function from
fasting glucose and insulin concentrations in man. Diabetologia. 1985;28:412–
419.
21. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, Kusek
JW, Eggers P, Van Lente F, Greene T, Coresh J; for the CKD-EPI (Chronic Kidney
Disease Epidemiology Collaboration). A new equation to estimate glomerular
filtration rate. Ann Intern Med. 2009;150:604–612.
22. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Report of the expert committee on the diagnosis and classification of diabetes
mellitus. Diabetes Care. 2003;26(suppl 1):S5–S20.
23. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, M€uller M. pROC:
an open-source package for R and S+ to analyze and compare ROC curves.
BMC Bioinformatics. 2011;12:77.
24. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathyphysiology and
treatment and therapeutic implication. J Am Coll Cardiol. 1993;22:318–325.
25. Czibik G, Steeples V, Yavari A, Ashrafian H. Citric acid cycle intermediates in
cardioprotection. Circ Cardiovasc Genet. 2014;7:711–719.
26. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major
energy source for cultured HeLa cells. J Biol Chem. 1979;254:2669–2676.
27. Dello SA, Neis EP, de Jong MC, van Eijk HM, Kicken CH, Olde Damink SW,
Dejong CH. Systematic review of ophthalmate as a novel biomarker of hepatic
glutathione depletion. Clin Nutr. 2013;32:325–330.
28. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, Kakazu Y,
Ishikawa T, Robert M, Nishioka T, Tomita M. Differential metabolomics reveals
ophthalmic acid as an oxidative stress biomarker indicating hepatic
glutathione consumption. J Biol Chem. 2006;281:16768–16776.
29. Ito T, Schaffer S, Azuma J. The effect of taurine on chronic heart failure:
actions of taurine against catecholamine and angiotensin II. Amino Acids.
2014;46:111–119.
30. Azuma J, Sawamura A, Awata N, Ohta H, Hamaguchi T, Harada H, Takihara K,
Hasegawa H, Yamagami T, Ishiyama T, Iwata H, Kishimoto S. Therapeutic
effect of taurine in congestive heart failure: a double-blind crossover trial. Clin
Cardiol. 1985;8:276–282.
31. Jeejeebhoy F, Keith M, Freeman M, Barr A, McCall M, Kurian R, Mazer D, Errett
L. Nutritional supplementation with MyoVive repletes essential cardiac
myocyte nutrients and reduces left ventricular size in patients with left
ventricular dysfunction. Am Heart J. 2002;143:1092–1100.
32. Beyranvand MR, Khalafi MK, Roshan VD, Choobineh S, Parsa SA, Piranfar MA.
Effect of taurine supplementation on exercise capacity of patients with heart
failure. J Cardiol. 2011;57:333–337.
33. Li P, Yin YL, Li D, Kim SW, Wu G. Amino acids and immune function. Br J Nutr.
2007;98:237–252.
34. Shi W, Meininger CJ, Haynes TE, Hatakeyama K, Wu G. Regulation of
tetrahydrobiopterin synthesis and bioavailability in endothelial cells. Cell
Biochem Biophys. 2004;41:415–434.
35. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM.
Antiinflammatory properties of HDL. Circ Res. 2004;95:764–772.
36. Repetto MG, Ossani G, Monserrat AJ, Boveris A. Oxidative damage: the
biochemical mechanism of cellular injury and necrosis in choline deficiency.
Exp Mol Pathol. 2010;88:143–149.
37. Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC, Bouatra S,
Anderson T, Oudit GY,Wishart DS, Dyck JR, Alberta H.Metabolomic fingerprint of
heart failure with preserved ejection fraction. PLoS One. 2015;10:e0124844.
38. Krim SR, Campbell P, Lavie CJ, Ventura H. Micronutrients in chronic heart
failure. Curr Heart Fail Rep. 2013;10:46–53.
39. Knez J, Winckelmans E, Plusquin M, Thijs L, Cauwenberghs N, Gu Y, Staessen
JA, Nawrot TS, Kuznetsova T. Correlates of peripheral blood mitochondrial DNA
content in a general population. Am J Epidemiol. 2016;183:138–146.
DOI: 10.1161/JAHA.115.002681 Journal of the American Heart Association 13
Diastolic LV Function and Metabolic Biomarkers Zhang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at KU Leuven University Library on April 12, 2016http://jaha.ahajournals.org/Downloaded from 
Redón and Jan A. Staessen
Monleon, Lotte Jacobs, Tim Nawrot, Peter Verhamme, Jens-Uwe Voigt, Tatiana Kuznetsova, Josep 
Zhen-Yu Zhang, Vannina G. Marrachelli, Lutgarde Thijs, Wen-Yi Yang, Fang-Fei Wei, Daniel
General Population
Diastolic Left Ventricular Function in Relation to Circulating Metabolic Biomarkers in a
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.115.002681
2016;5:e002681; originally published March 29, 2016;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/5/3/e002681
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 at KU Leuven University Library on April 12, 2016http://jaha.ahajournals.org/Downloaded from 
